Mayo Clinic and WuXi AppTec Group (“WuXi AppTec”) announced today a joint venture to co-develop and deliver clinical diagnostic services in China. The new entity will accelerate the development of novel esoteric tests that both organizations will offer in their respective markets. The intent is to benefit not only patients in China but also around the world.
“Through this agreement, WuXi AppTec will have access, through an exclusive partnership, to Mayo-developed tests and will be able to offer those tests to hospitals, health care providers, and patients in China,” says William Morice, II, M.D., Ph.D., president of Mayo Medical Laboratories and chair of Laboratory Medicine and Pathology at Mayo Clinic. “We expect this new venture to accelerate diagnostics research in our laboratory as well, transforming discoveries into tests that will benefit all patients.”
WuXi AppTec provides a broad and integrated portfolio of laboratory and manufacturing services throughout its research and development processes. The newly created company will combine WuXi AppTec’s operational excellence with Mayo Medical Laboratories’ clinical and laboratory testing expertise.
“We are excited to work with Mayo Clinic to bring a highly innovative, world-class diagnostics testing portfolio to China,” says Jason Liu, Ph.D., senior vice president of WuXi AppTec Group and chief operating officer of the company’s laboratory testing division. “This collaboration is a great fit with our mission to bring the best testing solutions from research to clinical practice. As one of the most highly regarded medical institutions in the world, Mayo Clinic will help transform China’s diagnostic landscape, improve the quality of patient care, and accelerate precision medicine in China.”
“The strategic collaboration with Mayo Clinic is a big step forward to fulfill WuXi AppTec’s dream that every drug can be made, every disease can be treated,” says Ge Li, Ph.D., chairman and CEO of WuXi AppTec Group. “Through the collaboration with Mayo, we’re committed to building a leading diagnostic services operation in China and co-developing in ways that will benefit our patients, doctors, and innovative collaborators in all corners of the world.”
About WuXi AppTec Group
WuXi AppTec Group is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec Group provides a broad and integrated portfolio of services to help its worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device research and development (R&D) through cost-effective and efficient solutions. With its industry-leading capabilities in small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics, WuXi AppTec Group is enabling more than 3,000 innovative collaborators from more than 30 countries to bring innovative health care products to patients and to fulfill WuXi AppTec Group’s dream that “every drug can be made and every disease can be treated.” Visit wuxiapptec.com. For specific information on WuXi AppTec Group’s advanced therapy manufacturing, visit us.wuxiapptec.com.